Newave Pharmaceutical Inc Report issue

For profit Phase 1
Founded: Pleasanton CA United States (2016)

Organization Overview

First Clinical Trial
2019
NCT04139434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Newave Pharmaceutical Inc

Active Ingredients

Drugs in Phase 1 Trials (3)

lp-108 (2 trials)

lp-118 (1 trial)

lp-168 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Recurrence (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 3